Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMP3-Mito Vaccine and ICI for Resectable Head and Neck Squamous Cell Carcinoma
NCT07572864Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jun 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in head and neck squamous cell carcinoma (HNSCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Major Pathologic Response at 6 weeks. Started Jun 2026; status: recruiting.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07572864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07572864.